Charles Wicks, MD
Cardiovascular Disease · Concord, NHNPI 1215092440
Payments from drug & device makers
What this record shows
Abbott accounts for 88.2% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $1,120, more than ten times the $102 reported in 2019.
Across 31 payments — averaging $54.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Abiomed$102
- Edwards Lifesciences$49
- Boston Scientific$36
- Johnson & Johnson$12
What the payments were for
- Travel & lodging$94956%
- Food & beverage$73344%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $1,484 |
| Abiomed | 1 | $102 |
| Edwards Lifesciences | 1 | $49 |
| Boston Scientific | 2 | $36 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,682 in reported general payments places this provider in the 65th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $167,362 |
| CamzyosMavacamten | 14 | $109,059 |
| XareltoRivaroxaban | 41 | $47,171 |
| EntrestoSacubitril/Valsartan | 34 | $43,246 |
| JardianceEmpagliflozin | 32 | $33,274 |
| Metoprolol Succinate | 157 | $1,914 |
| Atorvastatin Calcium | 156 | $1,231 |
| Dofetilide | 11 | $1,200 |
| Flecainide Acetate | 21 | $1,019 |
| ClopidogrelClopidogrel Bisulfate | 102 | $855 |
| Amiodarone Hcl | 32 | $777 |
| Potassium Chloride | 18 | $674 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $672 |
| Ezetimibe | 33 | $610 |
| Warfarin Sodium | 27 | $504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $12 | $47,17141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 cardiovascular disease providers in New Hampshire.
Other cardiovascular disease in Concord
- Ajay MishraConcord$6K
- Jonathan EddingerConcord$1K
- Michael NewtonConcord$854
- Fahad GilaniManchester$418K
- Stephan HeoManchester$116K
- Robert CapodilupoManchester$85K
- Kevin KwakuLebanon$79K
- Michael YoungLebanon$53K
- Jeanney LewManchester$36K
- Daniel PipilasDover$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.